Sentinel Lymph Node Biopsy in Melanoma
نویسندگان
چکیده
منابع مشابه
Sentinel lymph node biopsy correctly predicts regional lymph node recurrence in trunk malignant melanoma with multiple drainage basins
We report a young male with an initial excisional biopsy report of melanoma of the lower back, referred to our hospital for complete excision and sentinel lymph node (SLN) biopsy. Four peritumoral intradermal Tc-99m phytate injection was performed and SLNs were detected in both axillary and right inguinal regions. On the biopsy only the right axillary SLN was metastatic leading to right axilla...
متن کاملSentinel Lymph Node Biopsy in Melanoma
Sentinel lymph node (SLN) biopsy was first described by Morton et al. (1) in 1992 in patients with malignant melanoma. Many others over almost 100 y had made significant scientific contributions that ultimately led to the development of the technique (2–4); however, it was Morton’s group from the John Wayne Cancer Center that condensed the principle of the technique now used around the world. S...
متن کاملSentinel lymph node biopsy in melanoma.
The technique of lymphatic mapping and sentinel lymph node (SLN) biopsy for melanoma has emerged during the last 2 decades as a minimally invasive approach to evaluate regional lymph node basins in patients with intermediate- and high-risk primary cutaneous melanoma and has changed our approach to the clinically negative lymph node basin in melanoma during the same period. This review focuses o...
متن کاملRadiation exposure of the surgeons in sentinel lymph node biopsy
Background: Sentinel node biopsy (SLNB) is the standard of care for breast cancer treatment and it is getting wide acceptance in Iran. The radiation safety of the procedure has been investigated under controlled conditions, but the standard dose of radiotracer and techniques are not always observed in the community setting. The aim of this study was to assess the magnitude of the absor...
متن کاملSentinel-lymph-node biopsy for cutaneous melanoma.
Results: Positive SLNs were detected in 39 (15%) of 260 cases, including 0 (0%) of 45 for cutaneous melanomas 1.0 mm thick or less (T1), 21 (18%) of 115 for melanomas 1.01 to 2.0 mm thick (T2), 12 (19%) of 64 for melanomas 2.01 to 4.0 mm thick (T3), and 5 (16%) of 32 for melanomas thicker than 4.0 mm (T4). Median Breslow depths were 1.89 mm for SLN-positive biopsy specimens and 1.50 mm for SLN-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Cancer Journal
سال: 2012
ISSN: 1528-9117
DOI: 10.1097/ppo.0b013e31825046c7